The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

Inclusion Criteria Concurrent Medication: Allowed: * AZT, ddI, ddC, d4T, or 3TC. * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Rifabutin. * Clarithromycin. Patients must have: * HIV seropositivity. * Mean CD4 count \>= 100 cells/mm3. * External anogenital condyloma acuminatum confirmed by biopsy, present for less than 1 year. NOTE: * Warts on anal, urethral, or vaginal mucosa will not be studied. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Active lesions of genital herpes, other skin wounds, or active inflammatory skin disorders in the same area as warts to be treated. * Active medical problems sufficient to hinder study compliance. Concurrent Medication: Excluded: * Podofilox or any podophyllum resin preparation. * Liquid nitrogen treatment. * Interferon alpha. * Trichloracetic acid. * Other treatments, topical or systemic, surgical or ablative, known to have anti-papilloma activity. * Other investigative drugs (except d4T or 3TC) unless approved by the sponsor. Patients with the following prior conditions are excluded: History of untreated syphilis or Bowenoid papulosis. Prior Medication: Excluded within 4 weeks prior to study entry: * Treatment for anogenital warts. * Immunomodulators (including interferons or systemic corticosteroids). * Lymphocyte replacement therapy. * Biologic response modifiers. Substance abuse.